Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study
- Lisa A. Beck
- , Diamant Thaçi
- , Mette Deleuran
- , Marjolein de Bruin-Weller
- , Zhen Chen
- , Faisal A. Khokhar
- , Meng Zhang
- , Zafer E. Ozturk
- , Brad Shumel*
*Corresponding author for this work
- University of Rochester Medical Center
- Aarhus University
- Utrecht University
- Regeneron Pharmaceuticals, Inc.
- Sanofi S.A.
- Genzyme Corporation
15
Link opens in a new tab
Citations
(Scopus)